Earnings Feed
Start Free
MADRIGAL PHARMACEUTICALS, INC.·4

Mar 6, 5:55 PM ET

Soergel David 4

Research Summary

AI-generated summary

Updated

Madrigal (MDGL) CMO David Soergel Receives Stock Award

What Happened

David Soergel, Chief Medical Officer of Madrigal Pharmaceuticals (MDGL), was granted equity awards on March 4, 2026. The filing reports (1) 4,374 restricted stock units (RSUs) granted at $0 and (2) a derivative award for 5,467 shares (also granted at $0). These were grants/awards (code A) — not open-market purchases or sales — so no cash changed hands at grant.

Key Details

  • Transaction date: March 4, 2026; Form 4 filed March 6, 2026 (timely filing).
  • Grants reported: 4,374 RSUs and a 5,467-share derivative award; acquisition price shown as $0.00.
  • Shares owned after the transaction: not specified in the provided summary of the filing.
  • Footnotes:
    • F1: RSUs vest 25% on each of March 4, 2027, 2028, 2029 and 2030 (service-based vesting).
    • F2: The derivative award (option) vests 25% on March 4, 2027, then 6.25% at the end of each successive three-month period thereafter (service-based vesting).
  • Transaction code: A = Award/Grant.

Context

These awards are standard employee compensation that vest over time and do not indicate an immediate market transaction. For retail investors, purchases or open-market sales by insiders are generally a stronger near-term signal than routine grants, which are typically retention/compensation-related.